LSI Europe

The ABCs of LSI Europe ‘25: Today’s letter of the day is D for — Debate Session: Including Medtech, Biotech, or Healthtech in Your VC Thesis In this lively, unscripted debate, seasoned investors made their case for (and against) prioritizing medtech, biotech, or healthtech in their investment thesis. This session shared candid takes on market potential, risk profiles, regulatory complexity, and exit opportunities, plus where these sectors might overlap or compete for capital in the years ahead. This session featured:  • Dr. Luc Marengere — Managing Partner, TVM Capital Life Science • Brent Ahrens — General Partner, Canaan Partners • Ashley Seehusen — Venture Partner, SANTÉ Ventures • Luc Starmans — Partner, Brightlands Venture Partners • Daniel Allen, PhD — Principal, Unorthodox Ventures The video recording of this panel will be available in the coming weeks. Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25: Today’s letter of the day is D Here are the presenting companies who took the stage that start with the letter D: • DeepSight Technology — Diku Mandavia MD • Del Medtech — Steven Mickelsen • DIALYBRID — Stefania Adele Riboldi • Dxcover — Matthew J. Baker Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25: Today’s letter of the day is C for — Clinical Trial Design For startups aiming to raise capital, clinical data can be the tipping point. But generating the right kind of data at the right sites, with the right partners, can make all the difference. This panel, “Investor Ready vs Clinician Friendly Clinical Trial Design” brought together CEOs, investors, and clinical experts to share how strategic site partnerships can accelerate trials, strengthen credibility, and build the investor confidence needed to scale. This session featured:  • Aneta Sottil — Partner, Andera Partners • Stephen Wildhirt, M.D., Ph.D. — CEO & Co-Founder, AdjuCor GmbH • Marina Izzo — CEO, EBAMed • Marc Zemel — CEO, Retia Medical The video recording of this panel will be available in the coming weeks. Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25: Today’s letter of the day is C for — Commercializing Across Continents Bringing a product to market is never easy. Doing it across multiple healthcare systems adds even more complexity. This workshop explored how to navigate regulatory hurdles, payer dynamics, and go-to-market strategies in both the U.S. and Europe. This session featured:  • Pieter Wijffels — Venture Partner, NLC Health Ventures • Jeffrey Sirek — CEO, PRIA Healthcare • Timothy I. Still — Founder & Managing Director, TSTILL Enterprises LLC • Diego Serrano Cabrera — Investor, Sofina The video recording of this panel will be available in the coming weeks. Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25: Today’s letter of the day is C for — C-Sections, Chronic Woes, and Cutting-Edge Cures This session, “C-Sections, Chronic Woes, and Cutting-Edge Cures: Simon Tarry's Innovation Prescription,” explored the growing challenges of chronic wounds and surgical complications, including those related to C-sections. The panel discussed how innovation in advanced wound care is evolving to meet clinical needs, and share insights from his experience leading international markets at Smith + Nephew. This session featured Simon Tarry, SVP & General Manager Advanced Wound Management, International at Smith+Nephew, Victoria Beadle, Vice President Wound R&D, Smith + Nephew, and Moderator Andrew Pieprzyk, Vice President, Strategic Development - Diagnostics, International at Hologic, Inc. The video recording of this panel will be available in the coming weeks. Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25 — The letter of the day is C for CS Lifesciences, an LSI Europe ‘25 sponsor. CS Lifesciences is a trusted consultancy with offices in the UK, Ireland, and the USA, offering comprehensive support for Quality, Clinical, and Regulatory needs. Their extensive knowledge and expertise position them as a reliable partner for manufacturers of Medical Devices, In Vitro Diagnostics (IVD), and Clinical Diagnostics. The company provides end-to-end support, spanning product development, quality management system implementation, clinical trial management, regulatory submissions, and post-market support. Whether navigating FDA processes, securing CE Marks, or serving as an EU or UK Authorized Representative, CS Lifesciences guides manufacturers through the regulatory landscape, optimizing time and resources. Their practical, hands-on approach—refined through years of experience working with companies of varying sizes and specializations—ensures actionable advice and clear pathways to successful product approval. Thank you to CS Lifesciences for your unwavering commitment. Your partnership empowers us to support thousands of innovators, investors, and strategics worldwide as we work to move Medtech forward, together.

The ABCs of LSI Europe ‘25: Today’s letter of the day is C (Part 2) Here are the presenting companies who took the stage that start with the letter C: • Tripair™ developed by Coramaze — Jochen Reinöhl, MD, MSc • CorTec — Martin Schuettler • Corticale Srl — Fabio Boi • CorWave — Louis de Lillers • Cresilon — Joe Landolina • Crimson Scientific — Michael Cetta, MD FACEP FACHE • Crocevia Medical. — Tamir Nahmias • Cryosa Inc. — Laura Stoltenberg • CustomSurg — Valentin Christian Splett • Cypher Medical LLC — Chris Carew Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25: Today’s letter of the day is C (Part 1) Here are the presenting companies who took the stage that start with the letter C: • Caira Surgical — Jon Greenwald • Calla Lily Clinical Care — Lara Zibners MD MMEd MBA • CAPS Medical — Ilan Uchitel • Cardiawave — Carine Schorochoff • CDX Medical Technologies — Gopal Chopra • Cellviva — Rahul Chopra • CergenX — Jason Mowles • ChamberTech — Richard Chambers • Charco — Andrew Mullen • Circular Genomics — Paul Sargeant, PhD • Clairity, Inc. — Jeffrey R. Luber Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25: Today’s letter of the day is B for — Building Resilient Businesses Market shifts, regulatory changes, and capital constraints can challenge even the strongest companies. This panel, “Constructing Tomorrow: Building Resilient Businesses” focused on practical strategies leaders are using to build stability and adaptability into their organizations from the start. Panelists shared approaches to capital planning, forming strategic partnerships, retaining top talent, and navigating complex regulatory environments all with the goal of creating companies positioned for long-term success. This panel featured: • Lisa Carmel — Chair, Business Development, Mayo Clinic • Amy Kruse — Chief Investment Officer, Satori Capital • Agnieszka Janeczek — Founder & CEO, Renovos Biologics Limited • Hillary Pierce — CEO, Total Flow Medical The video recording of this panel will be available in the coming weeks. Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25

The ABCs of LSI Europe ‘25: Today’s letter of the day is B for — Buying to Build: Powering Growth with Strategic Acquisitions This workshop compared different approaches to using acquisitions as a catalyst for growth. Panelists shared how to identify the right targets, structure deals for long-term value, and integrate new assets effectively. Expect insights on balancing risk and reward, aligning acquisitions with core strategy, and leveraging M&A to accelerate innovation and market expansion. This session featured: • Ken Nelson — Partner, MedTech Advantage Fund • Dan Johnson — CEO, Instrumentum • Kevin Rocco — Partner, Neovate Capital Partners • Edward Ruppel III — Co-Founder, Director of R&D, Deerfield Catalyst The video recording of this session will be available in the coming weeks. Tune in each day as we recap LSI Europe ‘25 from A to Z. #LSIEurope25